Acute bacterial skin and skin structure infections in pediatric patients: potential role of dalbavancin

References

• Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018 Mar;16(3):143–155. Epub 2018 Jan 15
   PubMed Web of Science ®Google Scholar
• Watkins RR, David MZ. Approach to the Patient with a Skin and Soft Tissue Infection. Infect Dis Clin North Am. 2021 Mar; 35(1):1–48.
   PubMed Web of Science ®Google Scholar
• Wang V, Boguniewicz J, Boguniewicz M, et al. The infectious complications of atopic dermatitis. Ann Allergy Asthma Immunol. 2021 Jan;126(1):3–12. Epub 2020 Aug 7
   PubMed Web of Science ®Google Scholar
• Esposito S, Bassetti M, Concia E, et al. A literature review and consensus statement: an update. J Chemother. 2017 Aug;29(4):197–214.
   PubMed Web of Science ®Google Scholar
• Fritz SA, Shapiro DJ, Hersh AL. National Trends in Incidence of Purulent Skin and Soft Tissue Infections in Patients Presenting to Ambulatory and Emergency Department Settings, 2000-2015. Clin Infect Dis. 2020 Jun 10;70(12):2715–2718.
   PubMed Web of Science ®Google Scholar
• Lopez MA, Cruz AT, Kowalkowski MA, et al. Trends in resource utilization for hospitalized children with skin and soft tissue infections. Pediatrics. 2013 Mar;131(3):e718–25. Epub 2013 Feb 25
   PubMed Web of Science ®Google Scholar
• Moore SJ, O’Leary ST, Caldwell B, et al. Clinical characteristics and antibiotic utilization in pediatric patients hospitalized with acute bacterial skin and skin structure infection. Pediatr Infect Dis J. 2014 Aug;33(8):825–828.
   PubMed Web of Science ®Google Scholar
• Mistry RD, Shapiro DJ, Goyal MK, et al. Clinical management of skin and soft tissue infections in the U.S. Emergency Departments. West J Emerg Med. 2014 Jul;15(4):491–498.
   PubMedGoogle Scholar
• Moffarah AS, Al Mohajer M, Hurwitz BL, et al. Skin and Soft Tissue Infections. Microbiol Spectr. 2016Aug;4:4.
   Web of Science ®Google Scholar
• Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. N Engl J Med. 2017 Jun 29;376(26):2545–2555.
   PubMed Web of Science ®Google Scholar
• Barbic D, Chenkin J, Cho DD, et al. In patients presenting to the emergency department with skin and soft tissue infections what is the diagnostic accuracy of point-of-care ultrasonography for the diagnosis of abscess compared to the current standard of care? A systematic review and meta-analysis. BMJ Open. 2017 Jan 10;7(1):e013688. Erratum in: BMJ Open. 2017 Sep 14;7(9):e013688corr1
   PubMed Web of Science ®Google Scholar
• Klein EY, Mojica N, Jiang W, et al. Trends in Methicillin-Resistant Staphylococcus aureus Hospitalizations in the United States, 2010-2014. Clin Infect Dis. 2017 Nov 13;65(11):1921–1923.
   PubMed Web of Science ®Google Scholar
• Gorwitz RJ. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and update. Pediatr Infect Dis J. 2008 Oct;27(10):925–926.
   PubMed Web of Science ®Google Scholar
• Turner NA, Sharma-Kuinkel BK, Maskarinec SA, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019 Apr;17(4):203–218.
   PubMed Web of Science ®Google Scholar
• Gesualdo F, Bongiorno D, Rizzo C, et al. MRSA nasal colonization in children: prevalence meta-analysis, review of risk factors and molecular genetics. Pediatr Infect Dis J. 2013 May;32(5):479–485.
   PubMed Web of Science ®Google Scholar
• Creech CB 2nd, DS K, Alsentzer A, et al. Increasing rates of nasal carriage of methicillin-resistant Staphylococcus aureus in healthy children. Pediatr Infect Dis J. 2005 Jul;24(7):617–621.
   PubMed Web of Science ®Google Scholar
• Fritz SA, Garbutt J, Elward A, et al. Prevalence of and risk factors for community-acquired methicillin-resistant and methicillin-sensitive staphylococcus aureus colonization in children seen in a practice-based research network. Pediatrics. 2008 Jun;121(6):1090–1098.
   PubMed Web of Science ®Google Scholar
• Román F, Mendez-Echevarria A, Del Rosal T, et al. Characterization of methicillin-resistant Staphylococcus aureus strains colonizing the nostrils of Spanish children. Microbiologyopen. 2021 Oct;10(5):e1235.
   PubMed Web of Science ®Google Scholar
• Huang YC, Chen CJ. Community-associated meticillin-resistant Staphylococcus aureus in children in Taiwan, 2000s. Int J Antimicrob Agents. 2011 Jul;38(1):2–8. Epub 2011 Mar 11
   PubMed Web of Science ®Google Scholar
• Brink AJ, Richards GA. The role of multidrug and extensive-drug resistant Gram-negative bacteria in skin and soft tissue infections. Curr Opin Infect Dis. 2020 Apr;33(2):93–100.
   PubMed Web of Science ®Google Scholar
• Rosenberg MG. Clindamycin. Pediatr Rev. 1996 Oct;17(10):373–374.
   PubMedGoogle Scholar
• Smith MJ, Gonzalez D, Goldman JL, et al. Pharmacokinetics of Clindamycin in Obese and Nonobese Children. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02014–16.
   PubMed Web of Science ®Google Scholar
• Khamash DF, Voskertchian A, Tamma PD, et al. Increasing Clindamycin and Trimethoprim-Sulfamethoxazole Resistance in Pediatric Staphylococcus aureus Infections. J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):351–353.
   PubMed Web of Science ®Google Scholar
• Sutter DE, Milburn E, Chukwuma U, et al. Changing Susceptibility of Staphylococcus aureus in a US Pediatric Population. Pediatrics. 2016 Apr;137(4):e20153099. Epub 2016 Mar 1
   PubMed Web of Science ®Google Scholar
• Savage TJ, Sandora TJ. Clostridioides difficile Infection in Children: the Role of Infection Prevention and Antimicrobial Stewardship. J Pediatric Infect Dis Soc. 2021 Nov 17;10(Supplement_3):S64–S68.
   PubMedGoogle Scholar
• Bowen AC, Carapetis JR, Currie BJ, et al. Sulfamethoxazole-Trimethoprim (Cotrimoxazole) for Skin and Soft Tissue Infections Including Impetigo, Cellulitis, and Abscess. Open Forum Infect Dis. 2017 Nov 2;4(4):ofx232.
   PubMed Web of Science ®Google Scholar
• Cunha BA, Baron J, Cunha CB. Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations. Eur J Clin Microbiol Infect Dis. 2018 Jan;37(1):15–20. Epub 2017 Aug 17
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Brady MT, Jackson MA. Antimicrobial Resistance and Antimicrobial Stewardship: appropriate and Judicious Use of Antimicrobial Agents. Red Book (2018): report of the Committee on Infectious Diseases, AAP Committee on Infectious Diseases. May 2018. Available at: https://publications.aap.org/aapbooks/book/546/chapter-abstract/5811352/Antimicrobial-Resistance-and-Antimicrobial?redirectedFrom=fulltext. Last accessed 2022 Dec 27.
   Google Scholar
• Bidell MR, Lodise TP. Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: focus on doxycycline, minocycline, and omadacycline. Pharmacotherapy. 2021 Nov;41(11):915–931. Epub 2021 Oct 5
   PubMed Web of Science ®Google Scholar
• Briscoe CC, Reich P, Fritz S, et al. Staphylococcus aureus antibiotic susceptibility patterns in pediatric atopic dermatitis. Pediatr Dermatol. 2019 Jul;36(4):482–485. Epub 2019 May 24
   PubMed Web of Science ®Google Scholar
• Hwang D, Chiu NC, Chang L, et al. Vancomycin dosing and target attainment in children. J Microbiol Immunol Infect. 2017 Aug;50(4):494–499. Epub 2015 Sep 18
   PubMedGoogle Scholar
• Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020 May 19;77(11):835–864.
   PubMed Web of Science ®Google Scholar
• Zeng D, Debabov D, Hartsell TL, et al. Approved Glycopeptide Antibacterial Drugs: mechanism of Action and Resistance. Cold Spring Harb Perspect Med. 2016 Dec 1;6(12):a026989.
   PubMed Web of Science ®Google Scholar
• Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009 Oct;53(10):4069–4079. Epub 2009 Jul 13
   PubMed Web of Science ®Google Scholar
• Zhao W, Zhang D, Storme T, et al. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease. Br J Clin Pharmacol. 2015 Nov;80(5):1197–1207. Epub 2015 Sep 5
   PubMed Web of Science ®Google Scholar
• Loane G, Gwee A. Teicoplanin Therapeutic Drug Monitoring and Treatment Outcomes in Children With Gram-Positive Infections. J Pediatric Infect Dis Soc. 2021 May 28;10(5):682–685.
   PubMed Web of Science ®Google Scholar
• Chiappini E, Conti C, Galli L, et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther. 2010 Jan;32(1):66–88.
   PubMed Web of Science ®Google Scholar
• Yue J, Dong BR, Yang M, et al. Linezolid versus vancomycin for skin and soft tissue infections. Cochrane Database Syst Rev. 2016 Jan 7;(1): CD008056
   PubMed Web of Science ®Google Scholar
• Bayram N, Düzgöl M, Kara A, et al. Linezolid-related adverse effects in clinical practice in children. Arch Argent Pediatr. 2017 Oct 1;115(5):470–475.
   PubMed Web of Science ®Google Scholar
• Mensa Vendrell M, Tasias Pitarch M, Salavert Lletí M, et al. Safety and Tolerability of More than Six Days of Tedizolid Treatment. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00356–20.
   PubMed Web of Science ®Google Scholar
• Li D, Sabato PE, Guiastrennec B, et al. Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0089521. Epub 2021 Sep 13
   PubMed Web of Science ®Google Scholar
• Syrogiannopoulos GA, Michoula AN, Petinaki E, et al. Daptomycin Use in Children: experience With Various Types of Infection and Age Groups. Pediatr Infect Dis J. 2017 Oct;36(10):962–966.
   PubMed Web of Science ®Google Scholar
• Bradley J, Glasser C, Patino H, et al. Daptomycin for Complicated Skin Infections: a Randomized Trial. Pediatrics. 2017 Mar;139(3):e20162477. Epub 2017 Feb 15
   PubMed Web of Science ®Google Scholar
• Principi N, Caironi M, Venturini F, et al. Daptomycin in paediatrics: current knowledge and the need for future research. J Antimicrob Chemother. 2015 Mar;70(3):643–648. Epub 2014 Nov 17
   PubMed Web of Science ®Google Scholar
• Esposito S, Carrothers TJ, Riccobene T, et al. Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia. Paediatr Drugs. 2021 Nov;23(6):549–563. Epub 2021 Aug 31 Erratum in: Paediatr Drugs. 2021 Oct 7
   PubMed Web of Science ®Google Scholar
• Chen CW, Chang SP, Huang HT, et al. The efficacy and safety of ceftaroline in the treatment of acute bacterial infection in pediatric patients - a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019;12:1303–1310.
   PubMed Web of Science ®Google Scholar
• Gatti M, Andreoni M, Pea F, et al. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: a Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. Drug Des Devel Ther. 2021;15:3349–3378.
   PubMed Web of Science ®Google Scholar
• Oliva A, Stefani S, Venditti M, et al. Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin. Front Microbiol. 2021;12:749685.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Duncan LR, et al. Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. J Antimicrob Chemother. 2018 Oct 1;73(10):2748–2756.
   PubMed Web of Science ®Google Scholar
• Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother. 2006 Sep;58(3):627–631. Epub 2006 Jul 12
   PubMed Web of Science ®Google Scholar
• Molina KC, Miller MA, Mueller SW, et al. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. Clin Pharmacokinet. 2022 Mar;61(3):363–374. Epub 2021 Dec 21
   PubMed Web of Science ®Google Scholar
• Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother. 2005 Mar;55(Suppl 2):ii31–5.
   PubMed Web of Science ®Google Scholar
• Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother. 2004 Mar;48(3):940–945.
   PubMed Web of Science ®Google Scholar
• Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother. 2007 May;51(5):1633–1642. Epub 2007 Feb 16
   PubMed Web of Science ®Google Scholar
• Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008 Mar 1;46(5):668–674.
   PubMed Web of Science ®Google Scholar
• Rossi F, Diaz L, Wollam A, et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med. 2014 Apr 17;370(16):1524–1531. Erratum in: N Engl J Med. 2014 Jun 5;370(23):2253
   PubMed Web of Science ®Google Scholar
• Sader HS, Mendes RE, Duncan LR, et al. Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e02397–17.
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Flamm RK. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis. 2013 Mar;75(3):304–307. Epub 2013 Jan 26
   PubMed Web of Science ®Google Scholar
• Werth BJ, Jain R, Hahn A, et al. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen. Clin Microbiol Infect. 2018 Apr;24(4):429.e1–429.e5. Epub 2017 Aug 3
   PubMed Web of Science ®Google Scholar
• Steele JM, Seabury RW, Hale CM, et al. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin. J Clin Pharm Ther. 2018 Feb;43(1):101–103. Epub 2017 Jun 19
   PubMed Web of Science ®Google Scholar
• Kussmann M, Karer M, Obermueller M, et al. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis. Emerg Microbes Infect. 2018 Dec 5;7(1):202.
   PubMedGoogle Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clin Infect Dis. 2016 Mar 1;62(5):545–551. Epub 2015 Nov 26
   PubMed Web of Science ®Google Scholar
• Bai F, Aldieri C, Cattelan A, et al. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther. 2020 Dec;18(12):1271–1279. Epub 2020 Aug 14
   PubMed Web of Science ®Google Scholar
• Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018 Apr;51(4):571–577. Epub 2017 Nov 24
   PubMed Web of Science ®Google Scholar
• Arrieta-Loitegui M, Caro-Teller JM, Ortiz-Pérez S, et al. Effectiveness, safety, and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm. 2022 Jan;29(1):55–58. Epub 2020 Oct 5
   PubMedGoogle Scholar
• Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections. Int J Infect Dis. 2019 Apr;81:210–214. Epub 2019 Feb 19
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Gambardella M, Iula VD, et al. Current trends in the real-life use of dalbavancin: report of a study panel. Int J Antimicrob Agents. 2020 Oct;56(4):106107. Epub 2020 Jul 25.
   PubMed Web of Science ®Google Scholar
• Poliseno M, Bavaro DF, Brindicci G, et al. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections. Clin Drug Investig. 2021 May;41(5):437–448. Epub 2021 Apr 21
   PubMed Web of Science ®Google Scholar
• Simonetti O, Rizzetto G, Molinelli E, et al. Review: a Safety Profile of Dalbavancin for On- and Off-Label Utilization. Ther Clin Risk Manag. 2021;17:223–232.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Talbot GH, Boucher HW, et al. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: a Pooled Analysis of Randomized, Comparative Studies. Drug Saf. 2016 Feb;39(2):147–157.
   PubMed Web of Science ®Google Scholar
• Taylor K, Williamson J, Luther V, et al. Evaluating the Use of Dalbavancin for Off-Label Indications. Infect Dis Rep. 2022 Apr 11;14(2):266–272.
   PubMed Web of Science ®Google Scholar
• Sharma R, Francois D, Hammerschlag MR. New Antimicrobial Agents for the Treatment of Staphylococcal Infections in Children. Pediatr Clin North Am. 2017 Dec;64(6):1369–1387.
   PubMed Web of Science ®Google Scholar
• Zinzi D, Vlachaki I, Falla E, et al. Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective. Eur J Health Econ. 2022 Nov;23(8):1371–1381. Epub 2022 Feb 3
   PubMed Web of Science ®Google Scholar
• Gonzalez PL, Rappo U, Mas Casullo V, et al. Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): nephrotoxicity Rates Compared with Vancomycin: a Post Hoc Analysis of Three Clinical Trials. Infect Dis Ther. 2021 Mar;10(1):471–481. Epub 2021 Jan 30
   PubMed Web of Science ®Google Scholar
• van den Anker J, Reed MD, Allegaert K, et al. Developmental Changes in Pharmacokinetics and Pharmacodynamics. J Clin Pharmacol. 2018 Oct;58(Suppl 10):S10–S25.
   PubMed Web of Science ®Google Scholar
• Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015 Mar;79(3):395–404.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Puttagunta S, Rubino CM, et al. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age. Pediatr Infect Dis J. 2015 Jul;34(7):748–752.
   PubMed Web of Science ®Google Scholar
• Azanza JR, Sádaba B, Reis J. Dalbavancina: parámetros farmacocinéticos y farmacodinámicos [Dalbavancin: pharmacokinetic and pharmacodynamic parameters]. Enferm Infecc Microbiol Clin. 2017 Jan;35(Suppl 1):22–27. Spanish.
   PubMedGoogle Scholar
• Pfaller MA, Mendes RE, Sader HS, et al. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). J Glob Antimicrob Resist. 2017 Dec;11:4–7. Epub 2017 Jul 19
   PubMed Web of Science ®Google Scholar
• Gonzalez D, Bradley JS, Blumer J, et al. Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age. Pediatr Infect Dis J. 2017 Jul;36(7):645–653.
   PubMed Web of Science ®Google Scholar
• Giorgobiani M, Burroughs MH, Antadze T, et al. The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections. Pediatr Infect Dis J. 2022 Dec 7; Epub ahead of print
   PubMedGoogle Scholar
• Carrothers TJ, Lagraauw HM, Lindbom L, et al. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients. Pediatr Infect Dis J. 2023 Feb 1;42(2):99–105. Epub 2022 Nov 15
   PubMedGoogle Scholar